Related Experiment Video
Updated: May 28, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide
Eli J Louwagie1, Jessica N Diego1, Crystal S Farooqi1
1Department of Internal Medicine, LewisGale Hospital Montgomery, Blacksburg, VA 24060, USA.
Abstract:
Euglycemic ketoacidosis (EKA) is a life-threatening condition characterized by ketone production leading to systemic acidosis, dehydration, and end-organ damage. It presents similarly to diabetic ketoacidosis, except that patients have normal to slightly elevated blood glucose levels. EKA is an increasingly recognized complication of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. Recently the novel dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide was approved for treatment of diabetes and weight loss. Here, we describe a unique case in which a patient placed on both an SGLT2 inhibitor and tirzepatide to treat type 2 diabetes was admitted to the intensive care unit (ICU) for EKA. To our knowledge, this is the first case detailing a patient developing this serious condition after starting tirzepatide for diabetes. The patient required treatment and monitoring in an ICU to make a full recovery. As tirzepatide is a relatively new medication whose side effect profile has yet to be fully characterized, clinicians should be aware of this rare yet potentially fatal complication.
More Related Videos
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: